Updated on 7 December 2012
Venus reaches out to all the significant markets across the globe with presence in five continents and 60 countries. We have received patents for our research products from the established markets such as Europe, US, Japan, Canada, South Africa, Australia and so on, wherein the company is soon going the launch its respective product line in Oncology and AMR segment to mark its presence there as well.
What is the status of your current R&D programme? Which are the latest technologies that have been developed at Venus?
Venus Medicine Research Center (VMRC) at Venus Remedies Limited is an interdisciplinary drug discovery and development center approved by the Department of Scientific & Industrial Research, Govt. of India. VMRC excels in translational medicine and pharmaceutics having an in-depth experience and expertise into novel drug delivery systems (NDDS) and targeted therapeutics.
VMRC has achieved significant breakthrough in small molecule research for developing products helpful to combat antimicrobial resistance utilizing novel targets and adjuvants which synergize with other antibiotics, minimizing potential for resistance. Significant breakthroughs have been achieved by VMRC in ‘Antibiotic Adjuvant Entities' for notable resistance barriers like ESBLs, 'plasmid encoded carbapenem resistant metalo-beta-lactamases', MRSA, bacterial biofilms and C. difficile infection.
Besides this, the R&D centre is also actively working on the Target Drug Delivery in Oncology and has come up with a novel concept of triple conjugate therapy, i.e. Drug-Protein-Polymer-Conjugate (DPPC). Drug and protein have been conjugated together with the help of polymer for the first time, which will not only reduce the amount of the drug to be targeted but will also be very cost-effective. At Venus Remedies Limited, research is continuous endeavor to keep on coming up with innovative breakthrough products to offer the best drugs focussed on improving the patients' outcomes.
Have you been involved in any public private partnerships with the government agencies? Please give examples.
Yes, we are currently partnered with Institute of Microbial Technology (IMTECH) and Punjab University to develop a typhoid diagnostic kit to reduce detection time from 48 hours (under the conventional Vidal test) to a few minutes. We possess the mandate to globally market this early detection kit with the objective to put this on shelves starting 2013-14. Meanwhile, VMRC is connected for various research activities with the academia worldwide.